Market Research Report
Global Blood Plasma Market (Immunoglobulin, Albumin, Factor VIII, & Alpha 1): Insights, Trends and Forecast (2019-2023)
|Published by||Koncept Analytics||Product code||897440|
|Published||Content info||109 Pages
Delivery time: 1-2 business days
|Global Blood Plasma Market (Immunoglobulin, Albumin, Factor VIII, & Alpha 1): Insights, Trends and Forecast (2019-2023)|
|Published: July 30, 2019||Content info: 109 Pages||
The global blood plasma market is estimated to reach US$29.50 billion in 2023, growing at a CAGR of 7% for the period spanning from 2019 to 2023. The factors such as progress in therapeutic protein development, new advances in production of plasma, growing aging population, increasing spending on medicines and rise in collection centers are expected to drive the market. However, growth of the industry will be challenged by high cost of treatment, and high R&D costs. A few notable trends include increase in fractionation capacity, and innovation in therapeutics.
The global blood plasma market is broadly segmented into four types which are Immunoglobulin, Albumin, Factor VIII, Alpha 1 and Others. Increased recognition and treatment of primary immunodeficiency (PI), use in new indications, and increasing consumption in low IG-use countries has driven the growth of immunoglobulin segment.
North America is the largest market for blood plasma due to its advanced infrastructure which has helped in increasing plasma collection over the time. The emerging economies like China have showed huge potential with increased imports of Albumin. Rising use of immunoglobulin and increasing incidence of immune and bleeding disorders propelled the demand for immunoglobulin in the Unites States.
The report provides a comprehensive analysis of the global blood plasma market, segmented into Immunoglobulin, Albumin, Factor VIII, Alpha 1 and Others.
The major regional markets (North America, Europe and APAC) have been analyzed, along with country coverage of the United States.
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Takeda Pharmaceutical, CSL Limited, Grifols S.A., Octapharma, Inc., ADMA Biologics and China Biologics) are also presented in detail.